Skip to content
Drybench

Drybench Patent.

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN, NDA 022314

The patents and exclusivities FDA's Orange Book lists for NDA 022314 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.

FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.

Orange Book captured
14 October 2026
Paragraph IV list captured
17 October 2026
Last checked
30 October 2026
Data-branch commit
dadcab56563716abea6c5e31a5e1970080c778ef

Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.

Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.

Open in the app

Listed protection

The Orange Book capture of 14 October 2026 lists no patent and no exclusivity for NDA 022314.

Products

Each product number FDA lists under NDA 022314, as listed. The sections below name products by these numbers.

  • Product 001 · EXFORGE HCT

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 5MG BASE;12.5MG;160MG
    Approval date as listed
    30 Apr 2009
    Type as listed
    RX
    Applicant as listed
    NOVARTIS PHARMACEUTICALS CORP

  • Product 002 · EXFORGE HCT

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 5MG BASE;25MG;160MG
    Approval date as listed
    30 Apr 2009
    Type as listed
    RX
    Applicant as listed
    NOVARTIS PHARMACEUTICALS CORP

  • Product 003 · EXFORGE HCT

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 10MG BASE;12.5MG;160MG
    Approval date as listed
    30 Apr 2009
    Type as listed
    RX
    Applicant as listed
    NOVARTIS PHARMACEUTICALS CORP

  • Product 004 · EXFORGE HCT

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 10MG BASE;25MG;160MG
    Approval date as listed
    30 Apr 2009
    Type as listed
    RX
    Applicant as listed
    NOVARTIS PHARMACEUTICALS CORP

  • Product 005 · EXFORGE HCT

    Dosage form; route
    TABLET;ORAL
    Strength
    EQ 10MG BASE;25MG;320MG
    Approval date as listed
    30 Apr 2009
    Type as listed
    RX
    Applicant as listed
    NOVARTIS PHARMACEUTICALS CORP

Listed patents

Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.

The Orange Book capture of 14 October 2026 lists no patent for NDA 022314.

Listed exclusivities

Each exclusivity FDA lists for NDA 022314, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.

The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 022314.

Paragraph IV list rows giving NDA 022314

The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 022314, each cell as listed.

FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.

The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.

Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.

Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 022314

  • Amlodipine, Hydrochlorothiazide and Valsartan · Tablets · 10 mg/12.5 mg/ 160 mg

    RLD/NDA as listed: Exforge HCT 22314
    First PIV submission
    22 Oct 2009
    ANDAs
    1
    180-day status
    Eligible
    Decision posted
    11 Feb 2020
    First applicant approval
    25 Sep 2012
    First marketing
    1 Dec 2014
    Last qualifying patent expiry (as listed by FDA)
    18 Jul 2017

  • Amlodipine, Hydrochlorothiazide and Valsartan · Tablets · 5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 mg

    RLD/NDA as listed: Exforge HCT 22314
    First PIV submission
    14 Sep 2009
    ANDAs
    1
    180-day status
    Eligible
    Decision posted
    11 Feb 2020
    First applicant approval
    25 Sep 2012
    First marketing
    1 Dec 2014
    Last qualifying patent expiry (as listed by FDA)
    18 Jul 2017

Notes from the trace

  • R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.

Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week